Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (CSE:BIOV)

0.2250 +0.0200 (+9.76%)
Streaming Delayed Price Updated: 2:27 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biovaxys Technology Corp

< Previous 1 2 Next >
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
Via FinancialNewsMedia
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION
Via FinancialNewsMedia
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
Via FinancialNewsMedia
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS
Via FinancialNewsMedia
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
Via FinancialNewsMedia
Topics Death
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
Via FinancialNewsMedia
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
FURTHER STUDY IN HUMANS SHOWS THAT THE DTH RESPONSE, THE BASIS FOR CoviDTH, IS HIGHLY DURABLE AND PERSISTS FOR AT LEAST ONE YEAR AFTER COVID-19 EXPOSURE OR VACCINE ADMINISTRATION
Via FinancialNewsMedia
Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums
Via FinancialNewsMedia
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
Via FinancialNewsMedia
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
Via FinancialNewsMedia
Topics Death
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.